The strategic partnership EZZ has entered is expected to create world-leading products that cater to the specific needs and genetic makeup of each customer. 

Australian genomic life science company EZZ Life Science (ASX: EZZ) have entered a tripartite agreement to escalate its anti-ageing, gene research and immunology capabilities.

The company announced that it has signed a strategic partnership with leading multinational pharmaceutical companies GMP Pharmaceuticals (GMP) and Natural Innovations Group (NIG).

The partnership aims to develop and bring new products and wellness solutions to the market worldwide, with a focus on improving the health and wellbeing of people.

Under the agreement, the three companies will focus on new, world-leading opportunities in gene research, anti-ageing and immunology by leveraging NIG and GMP’s existing scientific research capabilities.

Gene tech and big data

The emphasis here will be on utilising gene technology and big data, which will enable EZZ to provide high quality, cutting-edge products to its consumers worldwide.

Chair of EZZ Life Science, Glenn Cross, said this approach would result in more effective and customised products, as well as improved quality control and better customer experiences.

“Both GMP and NIG have been closely involved with some of the world’s best-selling and most popular formulations in the dietary supplement market and EZZ is thrilled to partner with them,” he said.

“Both companies have a reputation for partnering with only the best brands in the world, so this is a huge endorsement for the company.”

A shared passion

EZZ says the new collaboration is driven by all three companies’ shared passion to not only improve the health of individuals, but also to extend lifespans and promote genetic longevity.

Through this agreement, the partners will work together to leverage their respective expertise and develop new gene technology for the lucrative dietary supplement market.

The collaboration will involve integrating advanced genetic testing analysis with the development of customised dietary supplements.

The goal is to create products that cater to the specific needs and genetic makeup of each individual customer.

Co-founder of NIG, Michael Henain, said it was a significant milestone for all three companies.

“This agreement opens the door to deliver the latest in wellness innovation to all EZZ consumers around the world,” Henain said.

“I believe the collaboration will provide consumers around the world the most effective and superior products available.”

Meanwhile Daniel Xu, Chief Operating Officer at GMP believes that collaboration is essential to create the best product for the market.

“The partnership highlights the importance of using new technology in the wellness industry, and also the need for companies to collaborate and work together to provide the best possible products and services to customers.”

“GMP is excited to leverage its state-of-the art technology to bring new products to life,” Xu added.

The partnership follows the recent approval of NMN (nicotinamide mononucleotide) supplements as food additives in China.

That approval is expected to launch EZZ further into the Chinese supplements market, which is projected to reach US$386m by the end of 2027.

This article was developed in collaboration with EZZ Life Science, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.